Transcat (TRNS) Competitors $68.50 -1.93 (-2.74%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$68.48 -0.02 (-0.02%) As of 10/10/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRNS vs. TXG, EYPT, AEHR, ALNT, LAB, CTKB, SENS, QSI, FEIM, and MASSShould you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Transcat vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Aehr Test Systems Allient Standard BioTools Cytek Biosciences Senseonics Quantum-Si Frequency Electronics 908 Devices Transcat (NASDAQ:TRNS) and 10x Genomics (NASDAQ:TXG) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Do institutionals & insiders have more ownership in TRNS or TXG? 98.3% of Transcat shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 2.8% of Transcat shares are held by insiders. Comparatively, 9.4% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is TRNS or TXG more profitable? Transcat has a net margin of 4.64% compared to 10x Genomics' net margin of -13.13%. Transcat's return on equity of 6.66% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Transcat4.64% 6.66% 5.09% 10x Genomics -13.13%-12.88%-10.03% Which has preferable valuation and earnings, TRNS or TXG? Transcat has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTranscat$288.14M2.22$14.52M$1.4347.9010x Genomics$610.78M2.34-$182.63M-$0.70-16.39 Which has more risk & volatility, TRNS or TXG? Transcat has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Does the media prefer TRNS or TXG? In the previous week, 10x Genomics had 3 more articles in the media than Transcat. MarketBeat recorded 8 mentions for 10x Genomics and 5 mentions for Transcat. Transcat's average media sentiment score of 1.02 beat 10x Genomics' score of 0.89 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TRNS or TXG? Transcat presently has a consensus target price of $112.20, indicating a potential upside of 63.80%. 10x Genomics has a consensus target price of $13.65, indicating a potential upside of 19.04%. Given Transcat's stronger consensus rating and higher probable upside, research analysts clearly believe Transcat is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Transcat 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.7110x Genomics 2 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.38 SummaryTranscat beats 10x Genomics on 10 of the 16 factors compared between the two stocks. Get Transcat News Delivered to You Automatically Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRNS vs. The Competition Export to ExcelMetricTranscatINSTRU IndustryComputer SectorNASDAQ ExchangeMarket Cap$638.31M$2.86B$32.13B$10.26BDividend YieldN/A1.07%3.22%4.76%P/E Ratio47.9026.33491.2226.55Price / Sales2.222.941,876.28191.87Price / Cash16.0514.5136.8160.57Price / Book2.223.647.416.52Net Income$14.52M$91.11M$820.34M$276.43M7 Day Performance-5.16%-4.83%-0.79%-0.88%1 Month Performance-8.45%0.84%4.66%3.48%1 Year Performance-45.85%17.17%24,132.45%30.15% Transcat Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRNSTranscat3.5265 of 5 stars$68.50-2.7%$112.20+63.8%-45.9%$638.31M$288.14M47.901,245News CoveragePositive NewsAnalyst UpgradeTXG10x Genomics3.9345 of 5 stars$12.64-0.9%$13.65+8.0%-29.5%$1.59B$610.78M-18.061,240News CoverageAnalyst UpgradeEYPTEyepoint Pharmaceuticals1.4506 of 5 stars$13.62-0.8%$26.86+97.2%+53.7%$946.37M$43.27M-5.08120News CoverageAnalyst ForecastAEHRAehr Test Systems1.7564 of 5 stars$31.65+2.0%N/A+46.6%$929.64M$58.97M-243.4490Trending NewsEarnings ReportAnalyst DowngradeInsider TradeAnalyst RevisionALNTAllient2.7054 of 5 stars$43.14-1.3%$35.00-18.9%+142.3%$741.09M$529.97M50.162,525News CoverageAnalyst ForecastLABStandard BioTools3.043 of 5 stars$1.32-1.5%$1.55+17.4%-32.3%$511.87M$174.43M-4.13620News CoverageAnalyst ForecastCTKBCytek Biosciences2.284 of 5 stars$4.02+1.3%$5.60+39.3%-23.2%$505.08M$200.45M-80.40500Positive NewsAnalyst ForecastSENSSenseonics2.1806 of 5 stars$0.57+22.0%$1.54+172.1%+18.1%$460.30M$25.47M-4.3590News CoverageHigh Trading VolumeQSIQuantum-Si2.4664 of 5 stars$1.81+5.2%$3.48+92.0%+101.9%$348.29M$3.06M-2.66150News CoverageAnalyst ForecastGap UpFEIMFrequency Electronics2.9706 of 5 stars$38.27+9.6%$43.00+12.4%+176.4%$340.35M$69.81M16.71200Analyst ForecastMASS908 Devices1.7798 of 5 stars$8.76-3.4%$8.00-8.7%+130.5%$325.26M$59.63M-16.2260Analyst Forecast Related Companies and Tools Related Companies TXG Competitors EYPT Competitors AEHR Competitors ALNT Competitors LAB Competitors CTKB Competitors SENS Competitors QSI Competitors FEIM Competitors MASS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRNS) was last updated on 10/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredBitcoin hits $125K… but the real story is hiding elsewhereA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Transcat, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Transcat With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
